Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Francisco, California. Our goal is to build an enduring biopharmaceutical company with compounds from our own research efforts that represent significant advances in the fields of thrombosis and other hematologic diseases. Each of our therapies has the potential to address a significant unmet need. We are advancing our candidates [Betrixaban, Andexanet alfa, Cerdulatinib] using novel biomarker and genetic approaches.